Genentech and NVIDIA enter drug discovery AI collaboration

21 November 2023
genentech-large

A new multi-year collaboration between Swiss pharma giant Roche (ROG: SIX) subsidiary Genentech and US tech firm NVIDIA (Nasdaq: NVDA) aims to transform the discovery and development of new medicines by bringing together experts from each company to optimize and accelerate Genentech’s proprietary algorithms.

NVIDIA will work with Genentech to accelerate these models on NVIDIA DGX Cloud, which provides dedicated instances of AI supercomputing and software hosted by NVIDIA cloud service provider partners.

Genentech says it plans to use NVIDIA BioNeMo, which enables biotech companies to customize models at scale, and integrate BioNeMo cloud application programming interfaces directly into computational drug discovery workflows.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology